Skip to main content

ALSUntangled #65: glucocorticoid corticosteroids.

Publication ,  Journal Article
Goslinga, JA; Terrelonge, M; Bedlack, R; Barkhaus, P; Barnes, B; Bertorini, T; Bromberg, M; Carter, G; Chen, A; Crayle, J; Dimachkie, M ...
Published in: Amyotroph Lateral Scler Frontotemporal Degener
May 2023

ALSUntangled reviews alternative and off-label treatments for people with amyotrophic lateral sclerosis (PALS). Here we review glucocorticoids. Neuroinflammation plays a prominent role in amyotrophic lateral sclerosis (ALS) pathogenesis, so some hypothesize that glucocorticoids might be an effective ALS therapy through their immunosuppressive effects. In this paper, we review the available evidence for glucocorticoids in ALS, including one pre-clinical study with a genetic mouse model of ALS, nine case reports (ranging from 1 to 26 patients each), and four clinical trials. We also review the possible side effects (including steroid myopathy) and the costs of therapy. We graded the level of evidence as follows: Mechanism, D; Pre-Clinical, F; Cases, B; Trials, F; Risks, C. Our review of the current evidence concludes that glucocorticoids do not offer clinical benefit in ALS and confer serious risks. Thus, ALSUntangled does not recommend glucocorticoids as a treatment for ALS.

Duke Scholars

Published In

Amyotroph Lateral Scler Frontotemporal Degener

DOI

EISSN

2167-9223

Publication Date

May 2023

Volume

24

Issue

3-4

Start / End Page

351 / 357

Location

England

Related Subject Headings

  • Mice
  • Humans
  • Glucocorticoids
  • Disease Models, Animal
  • Animals
  • Amyotrophic Lateral Sclerosis
  • 3209 Neurosciences
  • 1109 Neurosciences
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Goslinga, J. A., Terrelonge, M., Bedlack, R., Barkhaus, P., Barnes, B., Bertorini, T., … Wicks, P. (2023). ALSUntangled #65: glucocorticoid corticosteroids. Amyotroph Lateral Scler Frontotemporal Degener, 24(3–4), 351–357. https://doi.org/10.1080/21678421.2022.2099746
Goslinga, Jill Ann, Mark Terrelonge, Richard Bedlack, Paul Barkhaus, Benjamin Barnes, Tulio Bertorini, Mark Bromberg, et al. “ALSUntangled #65: glucocorticoid corticosteroids.Amyotroph Lateral Scler Frontotemporal Degener 24, no. 3–4 (May 2023): 351–57. https://doi.org/10.1080/21678421.2022.2099746.
Goslinga JA, Terrelonge M, Bedlack R, Barkhaus P, Barnes B, Bertorini T, et al. ALSUntangled #65: glucocorticoid corticosteroids. Amyotroph Lateral Scler Frontotemporal Degener. 2023 May;24(3–4):351–7.
Goslinga, Jill Ann, et al. “ALSUntangled #65: glucocorticoid corticosteroids.Amyotroph Lateral Scler Frontotemporal Degener, vol. 24, no. 3–4, May 2023, pp. 351–57. Pubmed, doi:10.1080/21678421.2022.2099746.
Goslinga JA, Terrelonge M, Bedlack R, Barkhaus P, Barnes B, Bertorini T, Bromberg M, Carter G, Chen A, Crayle J, Dimachkie M, Jiang L, Levitsky G, Lund I, Martin S, Mcdermott C, Pattee G, Pierce K, Ratner D, Slachtova L, Sun Y, Wicks P. ALSUntangled #65: glucocorticoid corticosteroids. Amyotroph Lateral Scler Frontotemporal Degener. 2023 May;24(3–4):351–357.

Published In

Amyotroph Lateral Scler Frontotemporal Degener

DOI

EISSN

2167-9223

Publication Date

May 2023

Volume

24

Issue

3-4

Start / End Page

351 / 357

Location

England

Related Subject Headings

  • Mice
  • Humans
  • Glucocorticoids
  • Disease Models, Animal
  • Animals
  • Amyotrophic Lateral Sclerosis
  • 3209 Neurosciences
  • 1109 Neurosciences
  • 1103 Clinical Sciences